Skip to main content

Table 3 Mechanistic studies: Urinary biochemistries in established AKI cases versus healthy controls

From: Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences

 

AKI patients

n available

Healthy controls

n available

T-test P

ANOVA P†

Wilcoxon rank P

Urine kallikrein (U/gm creatinine)

6.74 ± 1.92

18

0.63 ± 0.08

37

0.0058

0.00029

0.0012

Urine aldosterone (pg/mg creatinine)

9269.9 ± 2652.31

16

12982.4 ± 2619.78

38

0.325

0.65

0.1282

Urine epinephrine (ng/mg creatinine)

20.1 ± 2.4

14

7.48 ± 1.07

32

1.11E-06

0.00016

1.79E-05

Urine norepinephrine, (ng/mg creatinine)

37.15 ± 8.14

14

26.85 ±

3.2

32

0.344

0.16

0.4424

Urine kallikrein/urine aldosterone ratio (mU/μg)

872.0 ± 277.5

15

160.5 ±

76.7

38

0.00027

8.45E-05

3.62E-05

Urine kallikrein/urine epinephrine ratio (mU/ng)

0.32 ± 0.13

13

0.18 ±

0.04

31

0.8465

0.8

0.899

  1. Plus-minus values are covariate-adjusted mean ± one SEM. N is the number of study subjects available to conduct each experiment. †Results are analyzed by one-way ANOVA, factoring for age, sex and race. Bold: p ≤ 0.05.